Omeros (NASDAQ:OMER) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research report released on Saturday morning.

Other equities analysts also recently issued research reports about the stock. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research note on Thursday, January 8th. WBB Securities reissued a “strong-buy” rating and issued a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. HC Wainwright lifted their price target on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $40.33.

Omeros Stock Up 2.6%

Shares of OMER opened at $12.82 on Friday. The company has a market capitalization of $908.94 million, a price-to-earnings ratio of -6.35 and a beta of 2.38. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65. The stock has a 50 day moving average price of $10.69 and a 200 day moving average price of $6.75.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.39. On average, equities analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Trading of Omeros

Several large investors have recently bought and sold shares of OMER. Wealth Enhancement Advisory Services LLC lifted its position in shares of Omeros by 9.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock valued at $545,000 after acquiring an additional 2,631 shares in the last quarter. Harbour Investments Inc. raised its stake in Omeros by 46.1% in the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,251 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 5,677 shares in the last quarter. Rhumbline Advisers lifted its holdings in Omeros by 7.1% in the 3rd quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 7,048 shares in the last quarter. Finally, Cypress Capital Group boosted its stake in shares of Omeros by 20.7% during the 2nd quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 7,200 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.